Recursion Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the SEC on November 2, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of October 26, 2026, the company reported 622,759,259 shares of Class A common stock outstanding.
  • Filer status: The company is classified as a large accelerated filer, not a smaller reporting company or emerging growth company.
  • Stock listing: Class A common stock (par value $0.00001) is listed on the Nasdaq Global Select Market under the ticker RXRX.
  • Clinical programs mentioned: The filing references ongoing discussions with the FDA regarding a registrational path for REC-4881 in familial adenomatous polyposis, and planned expansion of REC-1245 into indication-specific cohorts including endometrial cancer.
  • Collaboration activity: The filing references Sanofi's plans for a development candidate optioned under a collaboration, including the potential timing of a Phase 1 clinical trial and eligibility for future milestone payments and royalties.
  • Shell company status: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

Recursion Pharmaceuticals Reports Q3 2026 Financial Filing With Key Pipeline and Collaboration Updates

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) submitted its Form 10-Q for the quarterly period ended September 30, 2026, according to the filing. The company, headquartered at 41 S Rio Grande Street, Salt Lake City, UT 84101, reported 622,759,259 shares of Class A common stock outstanding as of October 26, 2026. The filing confirms the company's classification as a large accelerated filer under SEC rules.

According to the filing, the company's forward-looking disclosures address several active clinical and preclinical programs. These include ongoing FDA discussions about a registrational trial design for REC-4881 targeting familial adenomatous polyposis, and plans to expand the REC-1245 clinical trial into indication-specific cohorts, including endometrial cancer, at a selected expansion dose. The filing also notes the company's plans to pursue partnership opportunities for REC-617 and REC-3565 and to re-invest any proceeds into its long-term strategy.

The filing further discloses that Sanofi holds a development candidate optioned under a collaboration agreement, with the filing citing the potential timing of a Phase 1 clinical trial and Recursion's eligibility to receive future milestone payments and royalties. The company also disclosed its stated objective to reduce cash burn and to shift its wet-lab operations from data generation toward validation of AI-generated results. All forward-looking statements in the filing are the company's own and are subject to its cautionary language as described therein.

What Was Disclosed

Recursion Pharmaceuticals filed its Q3 2026 Form 10-Q, reporting 622,759,259 Class A shares outstanding as of October 26, 2026, and providing forward-looking disclosures on clinical programs including REC-4881, REC-1245, and its Sanofi collaboration.